European Review for Medical and Pharmacological Sciences 2020; 24: 10219-10221

Production and application of polyclonal antibodies against SARS-CoV-2 viral spike protein. Development to rapid, highly sensitive diagnosis kit for early Corona viral detection among the population

K. KAVITHAA[1], M. PAULPANDI[1], V. BALACHANDAR[2], M. RAMESH[3], A. NARAYANASAMY[1]

[1]Disease Proteomics Laboratory, Department of Zoology, School of Life Sciences, Bharathiar University, Coimbatore, TN, India
[2]Human Molecular Cytogenetics and Stem Cell Laboratory, Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore, TN, India
[3]Unit of Toxicology, Department of Zoology, Bharathiar University, Coimbatore, TN, India

Abstract. – Pathogenic novel coronavirus SARS-CoV-2 is a recently rising infection that causes a high death rate in contaminated individuals. Many of the individuals who are infected are unaware of the infection because they may be asymptomatic carriers of the virus.To early analyze the viral disease, we proposed advancement of SARS-CoV-2 spike (S) proteins-explicit polyclonal antibodies-based kit described in this specific circumstance. The tests, if made accessible from variety of makers, can help smooth out early immunodetection of the crown viral infection. The survey Safe and Patient Friendly Healthcare suggests early diagnosis as the key to patients recovering from this deadly ailment.

Key Words:
SARS-CoV-2, Spike protein, Diagnosis Kit, Corona viral control.

Introduction

A few quick diagnostic test kits, supposed purpose of-care or on-the-spot indicative test units are industrially accessible in many nations. Units for the determination of occasional viral diseases are particularly used to avoid the postponed analytic testing, which could influence antiviral treatment. Individuals with diabete mellitus, renal illness and pregnant women are at a higher risk of contracting SARS-CoV-2[1]. Along these lines, a state of-care system with the fast finding of COVID-19 diseases is vital for effective clinical treatment.A segment of the remedies are utilized to treat various illness, they are utilized again to treat COVID-19. The examiners likewise discovered competitors among aggravates that are in clinical preliminaries or that are the subject of early exploration. The new investigation raises the likelihood that this reaction may end up being an antiviral treatment. Current crown treatment alternatives are insufficient for theviral pathogenic potential. Till now there was no immunization accessible to treat COVID-19 contamination. Through this review we anticipate that the principle smart diagnostic medical device would enter into the evaluation process. Accessible powerful antiviral medications are lopinavir or ritonavir, interferon-1β, remdesivir, chloroquine, and a variety of customary medication items are found to be ineffective. The accessible, intravenous hyperimmune globulin taken from people and monoclonal antibodies might bepossible options for future remedies[2].

Existing Analytic Strategies

Because of the unexpected beginning of the COVID-19 pandemic, medicinal services suppliers worldwide left with a lack of approved and dependable approaches to affirm the analysis. Affirming who is affected or not by COVID-19 is basic to the effective administration and regulation of the infection. Current analytic choic-

Corresponding Authors: Arul Narayanasamy, MD; e-mail: swamyarul@gmail.com
Manickam Paulpandi, MD; e-mail: curlyproteomics@gmail.com

es are constrained both by the type of testing available and the dependability. At present there are four possible scenarios related to COVID-19 diagnosis: release of patients after false negative test, lack of proper safety measures, reinfection after recovery from COVID-19 which results in backslide due to underlying infection and change in the infection with new disease or side effects. As of now, there are no FDA-endorsed (Food and Drug Administration) analytic tests for COVID-19, yet more are opening up constantly through the FDA's expanded access program. Extended access, sometimes called "Humane Use" is the utilization of a medication, biologic, or clinical gadget not yet endorsed by the FDA outside of a clinical preliminary[1]. This technique speeds up FDA survey process.

Nucleic Acid Amplification Tests

Difficulty in getting a dependable bio-specimen test presents an extra test with NAATs (Nucleic acid amplification test). The current proposal for this test is to acquire bio-specimen tests from the oropharynx and the nasopharynx. For most reliable test the biospecimen is acquired from blood, urine, feces or the cheek. Scholars[3] have found that the method of acquiring bio-specimen may influence the reliability of the test. It is noteworthy that there is a 70% chance of false positive tests, so it is crucial to increase the reliability of the test.

CT Scan

Current examination shows that time sequencing CT sweeps might be the touchiest indicative testing technique accessible for the coronavirus which is equipped for yielding an exact conclusion quicker than RT-PCR of 3 days. There is as yet a false negative portion of ≥12% announced with endeavored CT determinations of COVID-19. Mass CT channels are furthermore not convenient to handle similar number of countries that need more CT machines, specialists, and radiologists to help pandemic testing rates. Most medical clinics in the United States have 1 or 2 CT machines, and it mostly takes specialists somewhere between five and 15 minutes to dissect one CT sweep and give an understanding.

Serological Tests/Immunoassays

Serological tests (ST) use a surface protein or a variety of infection peptides to catch antibodies explicit to the infection in patients' blood. As this test shows the body's invulnerable reaction to the infection, these tests affirm whether somebody got considerably contaminated after their insusceptible framework has cleared the infection; also, these tests can help track subjects exposed to the infection, however remaining asymptomatic.

Lab Developed Tests

Lab Developed Tests (LDT), including Lab Developed Home Tests, may contain the equivalent or comparative parts as IVD tests; created and used inside a similar office. Up to date, manyLDTs were developed with just a single accessible for emergency clinic use in the United States[4]. The drawback of these tests is that in the rush to make the test accessible, many of the administrative surveys did not expect these tests and the clinical legitimacy is not advertised before they enter the market. Although LDTs may contain the equivalent or comparative parts as IVD tests, they are not dependent upon similar viability guidelines. Another disadvantage of these tests is that they are prepared and dissected at the maker and not at the emergency clinics or test assortment sites, as a result, this makes some test kits ineffective during stockpiling and transport.

Future Perspectives

Mostly, the determination of viral disease is troublesome, becausefew emergency clinics have the clinical skills required. In this way, the current review suggests that another test pack that can undoubtedly and quickly analyze COVID-19 diseases without a requirement for a PCR is needed. A technique to quickly treat COVID-19 disease is essential for effective clinical treatment and the use of contamination control measures.We propose the creation of a counter acting agent against SARS-CoV-2 viral antigenic spike protein. This is novel in two regards: (i), the planning of the recombinant spike protein as antigen and the vaccination of rodents to raise polyclonal antisera (Figure 1); (ii) to set up the antigen, without utilizing or taking care of potential perilous SARS-CoV-2 infection. The recombinant spike protein can yield a lot of antigens melded with the transporter protein as bacterial strain. Then again, the recombinant spike protein structured by the particular arrangement with high explicitness and antigenicity, productively identify the viral disease. Besides, it is more affordable and requires a shorter chance to deliver.



Figure 1. Production of Polyclonal antibody against SARS-CoV-2 regarding viral spike protein.

Conclusions

We will assess the gathered test units with nasal wash from patients with COVID-19 side effects. As a control test, a current indicative unit for quick recognition of the COVID-19 was used. The present proposed work would enhance the new knowledge of early discovery of COVID-19. It would be considered as the normal and exact strategy to make into a significant recognizing technique with financially smart way.

Conflict of Interest

The Authors declare that they have no conflict of interests.

Acknowledgements

We would like to acknowledge the Council of Scientific and-Industrial Research (CSIR), New Delhi, for its helpin preparing this work under the name of CSIR-RA(09/472(0182)/2018/EMR-I and CSIRPOOLScientist Scheme-9062A.

References

1) Paulpandi M, Kavithaa K, Asaikkutti A, Balachandar V, Ayyadurai N, Arul N. Could host cell receptor alteration prevent SARS-CoV-2 viral entry? – Hype or hope. Eur Rev Med Pharmacol Sci 2020; 24: 4554 - 4557.
2) Balachandar M, Mahalaxmi I, KaavyaJ, Vivekanandhan G, Ajithkumar S, Arul N.COVID-19: emerging protective measures. Eur Rev Med Pharmacol Sci 2020; 24:3422-3425.
3) Normile D. Singapore claims first use of antibody test to track coronavirus infections. Science 2020;2-7.
4) Castillo M. The Industry of CT scanning. Am J Neuroradiol2012; 33: 583-585.